Clinical trials: Massive Pulmonary Embolism
Massive Pulmonary Embolism
Massive Pulmonary Embolism: Trial of Non-immunogenic Recombinant Staphylokinase VS Alteplase FORPE
Objective: to evaluate the efficacy and safety of the Recombinant Non-immunogenic Staphylokinase with its single bolus administration in comparison with the bolus-infusion administration of the Alteplase in patients with massive…
- Trial name
- NCT04688320
- Testing
- Recombinant nonimmunogenic staphylokinase, Alteplase
- Where
- 23 sites in Russia
- Volunteers
- 310 people
- Sponsor
- Supergene, LLC
Trauma
Pragmatic, Randomized Optimal Platelet and Plasma Ratios
Pragmatic, Randomized, Optimal Platelet and Plasma Ratios (PROPPR)is a Phase III trial designed to evaluate the difference in 24-hour and 30-day mortality among subjects predicted to receive massive transfusion ([MT] (defined as…
- Trial name
- PROPPR (NCT01545232)
- Testing
- 1:1:1 Blood Transfusion Ratio, 1:1:2 Blood Transfusion Ratio
- Where
- 12 sites in United States, Canada
- Volunteers
- 680 people
- Sponsor
- The University of Texas Health Science Center, Houston
Pulmonary Embolism, Acute Pulmonary Embolism
FlowTriever Pulmonary Embolectomy Clinical Study
Evaluate the safety and effectiveness of the FlowTriever System for use in the removal of emboli from the pulmonary arteries in the treatment of acute pulmonary embolism.
- Conditions
- Pulmonary Embolism, Acute Pulmonary Embolism, Submassive Pulmonary Embolism, Massive Pulmonary Embolism
- Trial name
- FLARE (NCT02692586)
- Testing
- FlowTriever System
- Where
- 18 sites in United States
- Volunteers
- 106 people
- Sponsor
- Inari Medical
Submassive Pulmonary Embolism
ULTrasound Accelerated ThrombolysIs of PulMonAry Embolism
The ULTIMA study is intended to prove that in patients with pulmonary embolism and a right ventricular end diastolic diameter to left ventricular end diastolic diameter ratio ≥1 (RV/LV ratio) will benefit from treatment with…
- Trial name
- ULTIMA (NCT01166997)
- Testing
- EkoSonic Endovascular System, Unfractionated heparin
- Where
- 10 sites in Germany, Switzerland
- Volunteers
- 59 people
- Sponsor
- Boston Scientific Corporation
Pulmonary Embolism With Acute Cor Pulmonale, Pulmonary Embolism
Standard-dose Apixaban AFtEr Very Low-dose ThromboLYSis for Acute Intermediate-high Risk Acute Pulmonary Embolism
The purpose of this study is to examine the degree to which pulmonary embolism (clot) can be dissolved when treated with a very low dose of a systemic thrombolytic drug (clot buster) along with standard anticoagulant therapy as…
- Conditions
- Pulmonary Embolism With Acute Cor Pulmonale, Pulmonary Embolism, Pulmonary Embolism With Pulmonary Infarction, Pulmonary Embolism Subacute Massive
- Trial name
- SAFE-LYSE (NCT03988842)
- Testing
- Alteplase, Unfractionated heparin, Apixaban
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Victor Tapson, MD
PE - Pulmonary Embolism, PE - Pulmonary Thromboembolism
FlowTriever for Acute Massive Pulmonary Embolism (FLAME)
To evaluate treatment outcomes of patients diagnosed with high-risk (massive) pulmonary embolism
- Trial name
- FLAME (NCT04795167)
- Where
- 11 sites in United States
- Volunteers
- 115 people
- Sponsor
- Inari Medical
Pulmonary Embolism
Multicenter, Nonrandomized, Prospective Study of Pulmonary Embolism Removal With the AngioJet 6F Ultra System
The purpose of this European Post Market Follow-up Plan is designed to evaluate the safety, efficacy, adverse events and any new information that may surface regarding the use of the AngioJet Ultra PE Thrombectomy Catheter System…
- Trial name
- PERFUSE (NCT01638468)
- Testing
- AngioJet Ultra PE Thrombectomy System
- Where
- 7 sites in Germany, Italy and 2 more
- Volunteers
- 7 people
- Sponsor
- Boston Scientific Corporation
Pulmonary Embolism, Acute Pulmonary Embolism
Submassive and Massive Pulmonary Embolism Treatment With Ultrasound Accelerated Thrombolysis Therapy
The purpose of this study is to determine if the EKOS EkoSonic® Endovascular Device when used in conjunction with recombinant tissue plasminogen activator (t-PA) as a treatment for acute PE will decrease the ratio of right…
- Conditions
- Pulmonary Embolism, Acute Pulmonary Embolism, Sub-massive Pulmonary Embolism, Massive Pulmonary Embolism
- Trial name
- SEATTLE II (NCT01513759)
- Testing
- recombinant tissue plasminogen activator, EKOS EkoSonic Endovascular System
- Where
- 22 sites in United States
- Volunteers
- 150 people
- Sponsor
- Boston Scientific Corporation